Latigo IPO plans amid Segro-Prologis battle
Latigo Biotherapeutics prepares public offering for non-opioid pain pipeline while Segro rejects third Prologis takeover bid.
Latigo Biotherapeutics is preparing an initial public offering to fund its clinical-stage pipeline of non-opioid pain management drugs, positioning itself as a potential rival to Vertex's Journax treatment. The biotech's move reflects continued investor appetite for alternatives to traditional opioid pain therapies amid the ongoing addiction crisis. Meanwhile, in a separate corporate development, London-listed Segro has rejected a £13.5 billion takeover bid from US rival Prologis, marking the third offer declined in an escalating battle for control of the industrial property group. Segro's board continues to resist Prologis's advances despite the substantial premium being offered, suggesting confidence in independent value or expectations for improved terms.
Sources · 2
Segro rejects £13.5bn bid by US rival Prologis in latest takeover twist
FT Companies
Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax
FierceBiotech
Matched signals
Lattice signals Numen pinned to this story at publish time.
No matched signals on this story.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →On X right now
Top engagement posts about this topic, ranked by likes + retweets + quotes.
No high-engagement X posts captured for this topic. Either the topic is too quiet or the upstream API was unavailable when this article published.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →Your read
How did this article land?
Three sliders. Optional comment. Anonymous is fine.
Open to anyone. One response per reader.